BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 15,720,000 shares, a decrease of 9.1% from the December 15th total of 17,290,000 shares. Based on an average daily trading volume, of 2,050,000 shares, the days-to-cover ratio is currently 7.7 days.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.45 on Friday. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s 50-day simple moving average is $7.57 and its 200-day simple moving average is $7.61. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -12.21 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.19) earnings per share. As a group, research analysts predict that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. Quantinno Capital Management LP acquired a new position in BioCryst Pharmaceuticals in the third quarter worth approximately $82,000. DRW Securities LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $74,000. Xponance Inc. lifted its position in shares of BioCryst Pharmaceuticals by 13.1% in the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,505 shares during the last quarter. Finally, SkyView Investment Advisors LLC boosted its position in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BCRX shares. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.17.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.